RxDoctor Payments Data

Kofi-Ann McDermott, NP

Nurse Practitioner · Atlanta, GANPI 1427821990

Payments from drug & device makers

$2,683in general payments, 2019–2025

Across 81 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$399
  • Incyte Corporation$236
  • Sanofi$233
  • AstraZeneca$215
  • Jazz Pharmaceuticals Inc.$149
  • Karyopharm Therapeutics Inc.$146
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,37188%
  • Education$31112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,683 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$8,735
Medicare patients
107
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib15$234,493
EliquisApixaban33$26,990
XareltoRivaroxaban18$17,839
Exemestane33$4,124
Letrozole109$2,348
Hydroxyurea24$939
Anastrozole49$554
ValacyclovirValacyclovir Hcl19$461
Gabapentin23$209
Ondansetron OdtOndansetron14$148
Zolpidem Tartrate12$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$26,99033 claims
Johnson & JohnsonXarelto$399$17,83918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →